Cagrilintide 5mg

CAS Number: 2413796-58-6
Synonyms: AM-833; Long-acting amylin analogue
Molecular Formula: C₁₈₈H₂₈₉N₅₁O₅₇S₂
Molecular Weight: 4221.7 g/mol
Sequence (Human Amylin Analogue):
Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Leu-Ser-Ser-Asn-Leu-Val-Gly-Ser-Asn-Thr-Ala-Val-Ser-Ser-Asn-Leu-Leu-Ala-Ala-Thr-Lys-Leu-Leu-Gln-Thr-Tyr-NH₂
Disulfide Bond: Cys2–Cys7
Purity: ≥ 98 % (HPLC)
Appearance: White to off-white lyophilized powder
Storage: –20 °C, desiccated, protected from light
Solubility: Soluble in water, DMSO, or dilute acetic acid

---

Description

Cagrilintide is a synthetic, long-acting analogue of the peptide hormone amylin, engineered to maintain receptor selectivity while improving stability and resistance to degradation. It acts as a high-affinity agonist at amylin receptor complexes, which consist of the calcitonin receptor (CTR) and receptor-activity-modifying proteins (RAMP1–3).

Through targeted amino-acid substitutions and lipidation, Cagrilintide demonstrates greatly reduced aggregation potential relative to native amylin and exhibits prolonged receptor engagement in experimental systems. Its structure includes a conserved N-terminal disulfide bond and a C-terminal amidation, both essential for bioactive conformation.

---

Research Applications

Cagrilintide is supplied for biochemical and receptor-binding research, structure–activity relationship studies, and metabolic signaling investigations involving amylin and calcitonin receptor families.
The compound serves as a model for exploring peptide stability, aggregation resistance, and extended-release pharmacology in peptide design.

---

Handling & Stability

• Reconstitute peptide in sterile water or aqueous buffer prior to use.

• Avoid repeated freeze–thaw cycles; aliquot after initial reconstitution.

• Store lyophilized material at –20 °C or below for long-term stability.

---

Specifications Summary

---

Background Information

Cagrilintide was created through rational peptide engineering to extend the half-life and receptor selectivity of amylin analogues.
Key design goals included:

• Incorporation of amino-acid substitutions to inhibit amyloid formation;

• Lipid conjugation to promote plasma-protein binding and enhance molecular stability;

• Optimization of the α-helical structure critical for receptor affinity.

The compound has been utilized in pre-clinical biochemical and structural studies to elucidate ligand–receptor interactions across the amylin–calcitonin receptor superfamily.

---

References

1. Østergaard S D et al. Development of a long-acting amylin analogue for metabolic research. J Med Chem. 2021; 64(14): 10494-10505. [PMID: 34288673]

2. Zhao Y et al. Structural and dynamic features of cagrilintide binding to amylin and calcitonin receptors. Nature.2024; 630: 453-459. [PMID: 40204768]

3. Darsalia V et al. Cagrilintide interactions with brain amylin receptors in metabolic models. Mol Metab. 2025; 95: 107842. [PMID: 40609154]